Trials / Completed
CompletedNCT01260506
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of VB-111 in patients with Relapsed Glioblastoma Multiforme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VB-111 | |
| DRUG | Bevacizumab | Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2015-07-23
- Completion
- 2018-12-20
- First posted
- 2010-12-15
- Last updated
- 2020-04-24
Locations
4 sites across 2 countries: United States, Israel
Source: ClinicalTrials.gov record NCT01260506. Inclusion in this directory is not an endorsement.